SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Prevail Therapeutics Inc. (Nasdaq – PRVL)

BALA CYNWYD – December 15, 2020 /Access Wire/ – Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Prevail Therapeutics Inc. (“Prevail” or the “Company”) (Nasdaq – PRVL) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the agreement to be acquired by Eli Lilly and Company (“Eli Lilly”) (NYSE – LLY). Under the terms of the agreement, Prevail shareholders will receive only $22.50 per share in cash plus one non-tradable contingent value right (“CVR”) worth up to $4.00 per share in cash if certain milestones are reached.

The investigation concerns whether the Prevail Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Eli Lilly is underpaying for the Company. For example, the deal consideration (without the potential CVR) is below the wall street analyst average twelve-month price target of $23.57 for Prevail shares.

If you own shares of Prevail stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, or call toll free 855-576-4847.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.